IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based generic topical pharmaceutical company, today announced that Dr. Kenneth Miller has been appointed Senior Vice President of R&D at IGI Laboratories, Inc. effective December 17, 2012. Jason Grenfell-Gardner, President and CEO of the Company, commented, “Dr. Miller’s appointment brings significant practical experience in generic topical pharmaceuticals and leadership that will allow us to accelerate the growth of our ANDA pipeline. This pipeline is the key to growing IGI’s generic business, and we’re excited to have Dr. Miller leading our R&D team.” Dr. Miller brings over twenty years of topical and transdermal experience in both branded and generic pharmaceutical product development. Prior to joining IGI Laboratories, Ken held various leadership positions at Mylan Technologies (formerly Bertek Inc.) eventually rising to Senior Director in 2008. In his role as head of product development, Ken oversaw the development of Mylan Technologies’ topical and transdermal patches including Mylan’s Fentanyl Transdermal System which received the DIANA Award for Best New Product Introduction in 2005. In addition to his contributions to product development, Ken was also responsible for technical evaluation of intellectual property for Mylan Technologies with four US Patents and six World Patents on product design and manufacture (additional patents pending). Prior to joining Mylan Technologies in 1998, Ken held positions in both industry and academia serving on the faculties of UAMS (Pharmaceutics), Penn State (Chemical Engineering) and Utah (Dermatology). He has a BSChE degree from Carnegie Mellon University, an MSChE degree from West Virginia University, and a PhD from the University of Florida. About IGI Laboratories, Inc. IGI Laboratories is a developer and manufacturer of topical formulations for the pharmaceutical, OTC, and cosmetic markets. Our mission is to be a leading player in the generic topical prescription drug market. IGI Laboratories, Inc. “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as "will," "possible," "one time," "provides an opportunity," "continue" or words of similar meaning. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors" in IGI Laboratories, Inc.’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Actual results may differ materially from these expectations due to changes in global political, economic, business, competitive, market and regulatory factors or IGI Laboratories, Inc.’s ability to implement business strategies. IGI Laboratories, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.